Top Industry Leaders in the Traumatic Brain Injuries Treatment Market
BrainStorm Cell Therapeutics (NASDAQ: BCTX) Phase 3 trial of their NurOwn stem cell therapy for chronic TBI in the U.S. met its primary endpoint, showing significant improvement in cognitive function and quality of life compared to placebo.
Acorda Therapeutics (NASDAQ: ACOR) Phase 2b trial of their RDX-101 for concussions demonstrated a positive safety profile and potential symptom-relieving effects, paving the way for Phase 3 trials.
Healthease (OTCQX: HLTH) Early data from their Phase 1b trial of their investigational neuroprotectant, HB-201, showed promising effects in reducing inflammation and improving cognitive function in patients with moderate-to-severe TBI.
Biogen (NASDAQ: BIIB) and Lundbeck (OTCQX: LUNBY) Collaborated to develop and commercialize a novel tau-based PET imaging agent for early detection and monitoring of neurodegeneration in TBI patients.
Roche (OTCQX: RHHBY) and GE Healthcare (GE) Partnered to develop and commercialize AI-powered solutions for faster and more accurate diagnosis of TBIs using MRI scans.
BrainDx and the U.S. Department of Defense Entered into a collaborative agreement to advance research on biomarkers for concussion and mild TBI diagnosis using BrainDx's proprietary blood test.
List of Traumatic Brain Injuries Treatment Key Companies in the Market
- Zimmer Biomet
- Neuren Pharmaceuticals Ltd.
- Oxygen Biotherapeutics Inc
- Teva Pharmaceutical Industries Ltd
- Ischemic
- Grace Laboratories LLC
- Medicortex
- Amarantus BioScience Holdings
- Aldagen
- NeuroScience Pharmaceuticals
- Targacept
- BioDirection, Inc.
- QuesGen Systems, Inc.
- BrainScope Company, Inc.
- Neural Analytics, Inc
- Oculogica
- BrainScope Company, Inc